Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8089461 | 0.88 | KDM4E (0.46) | TAAR1KDM4EL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL30885596 | 0.86 | KDM4E (0.49) | TAAR1KDM4EL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2772902 | 0.84 | KDM4E (0.44) | TAAR1KDM4EL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7592231 | 0.82 | TRPA1 (0.44) | TAAR1KDM4EL3MBTL1ALDH1A1TRPA1 | |
| SCHEMBL8959902 | 0.81 | TAAR1 (0.49) | TAAR1ALDH1A1SMN1; SMN2LMNATP53 | |
| SCHEMBL8430263 | 0.80 | SIGMAR1 (0.50) | TAAR1KDM4EL3MBTL1TRPA1 | |
| SCHEMBL15226978 | 0.79 | TAAR1 (0.47) | TAAR1KDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL13006647 | 0.79 | TAAR1 (0.47) | TAAR1KDM4ESMN1; SMN2LMNAMEN1 | |
| SCHEMBL26002686 | 0.79 | TAAR1 (0.47) | TAAR1KDM4EL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2002725 | 0.79 | TAAR1 (0.47) | TAAR1ALDH1A1SMN1; SMN2LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2819993-B1 | ROS-ACTIVATED COMPOUNDS AS SELECTIVE ANTI-CANCER THERAPEUTICS | UNIV CINCINNATI (US) | 2020-09-02 | — | — | EP | disclosed |
| US-9394233-B2 | ROS-activated compounds as selective anti-cancer therapeutics | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2016-07-19 | — | — | US | disclosed |
| EP-2819993-A1 | ROS-ACTIVATED COMPOUNDS AS SELECTIVE ANTI-CANCER THERAPEUTICS | University Of Cincinnati (US) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013130968-A1 | ROS-ACTIVATED COMPOUNDS AS SELECTIVE ANTI-CANCER THERAPEUTICS | UNIVERSITY OF CINCINNATI (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130230542-A1 | ROS-Activated Compounds as Selective Anti-Cancer Therapeutics | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2013-09-05 | — | — | US | disclosed |
| US-7256199-B1 | Pyrimidone derivatives | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-08-14 | — | — | US | disclosed |
| EP-1099692-B1 | N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-6737425-B1 | SUCH AS 1-((4-CYANO-5-METHYL-4-PHENYL)HEXYL)-4-(2-(4-FLUORO -PHENOXY)ETHYL)PIPERAZINE; NERVE SELECTIVE CALCIUM ANTAGONISTS | EISAI CO., LTD. (JP) | 2004-05-18 | — | — | US | disclosed |
| CN-1310709-A | N, N-substituted cyclic amine derivatives | EISAI CO LTD (JP) | 2001-08-29 | — | — | CN | disclosed |
| EP-1099692-A1 | N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2001-05-16 | — | — | EP | disclosed |
| US-3932379-A | Water-soluble maroon and rubine sulphodiphenylazophenyl- or naphthylazoaniline dyes for polyamide fibers | Althouse Tertre en abrege "Atsa" societe anonyme (BE) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230542-A1 | ROS-Activated Compounds as Selective Anti-Cancer Therapeutics | ROS1, NOX4, NOX1 | TAAR1 4043/4885KDM4E 3219/4885L3MBTL1 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.